Hoth Therapeutics announces the selection of Nuvisan for manufacturing HT-001 drug batches for CLEER-001 clinical study for cancer patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with Nuvisan, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture clinical batches of HT-001 topical drug product for its upcoming CLEER-001 clinical trial for cancer patients. HT-001 is a novel topical therapy in development for treatment of cutaneous toxicities associated with Epidermal Growth Factor Receptor (EGFR) inhibitor cancer therapy.

READ MORE